ACCM launches legislative medical cannabis toolkit

💊 As organized medicine increasingly engages in cannabis policy advocacy through toolkits and legislative frameworks, clinicians should recognize that professional guidance on medical cannabis remains fragmented across medical boards, specialty societies, and advocacy organizations. The ACCM’s legislative toolkit likely reflects efforts to standardize recommendations and educate policymakers, yet individual state regulations, variable product quality standards, and limited robust clinical trial data continue to complicate clinical decision-making at the bedside. Healthcare providers should be aware that enthusiasm from advocacy organizations may not fully align with the evidence base for specific conditions, and that recommending or discussing cannabis with patients requires awareness of both potential benefits in selected cases and significant unknowns regarding long-term effects, drug interactions, and population-specific harms. Rather than deferring to policy frameworks alone, clinicians should maintain critical appraisal of the cannabis literature for their specific patient populations while documenting recommendations clearly and ensuring patients understand the current evidence gaps. A